Bone Markers and Osteoporosis Therapy
Overview
Authors
Affiliations
Several factors are involved in determining bone quality including bone density, bone turnover, the extent of trabecular bone connectivity, cortical porosity and geometry. Metabolically active and in a continuous process of remodeling, approximately 20% of bone tissue is renewed annually. Bone turn over markers (BTM) are frequently used in clinical trials and to provide valid information about the effectiveness of osteoporosis treatment, reflecting the state of bone metabolism and its response to treatment, although they are not useful alone to estimate bone loss. In this review the behavior of BTM from different clinical trials or different osteoporotic drugs will be addressed.
Zhang Q, Gao W, Xu X, Cui R, Su B Osteoporos Int. 2025; .
PMID: 40038109 DOI: 10.1007/s00198-025-07448-7.
Zhang J, Li Y, Lai D, Lu D, Lan Z, Kang J Front Public Health. 2022; 9:727132.
PMID: 35223754 PMC: 8873521. DOI: 10.3389/fpubh.2021.727132.
Ding X, Yang L, Hu Y, Yu J, Tang Y, Luo D Am J Transl Res. 2019; 11(9):5417-5437.
PMID: 31632520 PMC: 6789268.
Pan B, Wu L, Pan L, Yang Y, Li H, Dai Y Biosci Rep. 2018; 38(4).
PMID: 29769415 PMC: 6117618. DOI: 10.1042/BSR20171615.
Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
Festuccia F, Jafari M, Moioli A, Fofi C, Barberi S, Amendola S J Nephrol. 2016; 30(2):271-279.
PMID: 27394428 DOI: 10.1007/s40620-016-0334-1.